A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs KD 025 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 03 Aug 2017 According to a Kadmon media release, approximately 50% patients have been enrolled.
    • 23 Jun 2017 Planned number of patients changed from 150 to 180.
    • 22 Mar 2017 According to a Kadmon media release, the company expects completion of enrollment in mid-2017 and anticipates data from this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top